|
|
Blood, 15 July 2007, Vol. 110, No. 2, pp. 719-726.
Prepublished online as a Blood First Edition Paper on April 9, 2007; DOI 10.1182/blood-2007-01-068809.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders
John M. Joslin1,
Anthony A. Fernald1,
Thelma R. Tennant1,
Elizabeth M. Davis1,
Scott C. Kogan2,
John Anastasi3,
John D. Crispino4, and
Michelle M. Le Beau1
1 Section of Hematology/Oncology and the Cancer Research Center, University of Chicago, IL;
2 Department of Laboratory Medicine, University of California at San Francisco;
3 Department of Pathology
4 Ben May Department for Cancer Research, University of Chicago, IL
Loss of a whole chromosome 5 or a deletion of the long arm, del(5q), is a recurring abnormality in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML). To identify a leukemia-related gene on chromosome 5, we previously delineated a 970-kb segment of 5q31 that is deleted in all patients examined, and prepared a transcript map of this region. EGR1 is a candidate tumor suppressor gene within the commonly deleted segment of 5q, and encodes a zinc finger transcription factor. To test the hypothesis that loss of function of Egr1 is an initiating event in the pathogenesis of AML/MDS, Egr1-deficient mice were treated with a potent DNA alkylating agent, N-ethyl-nitrosourea (ENU), to induce secondary cooperating mutations. Egr1+/– and Egr1–/– mice treated with ENU developed immature T-cell lymphomas (CD4+, CD8+) or a myeloproliferative disorder (MPD) at increased rates and with shorter latencies than that of wild-type littermates. The MPD was characterized by an elevated white blood cell count, anemia, and thrombocytopenia with ineffective erythropoiesis. Biallelic mutations of Egr1 were not observed in MPDs in Egr1+/– mice. Our data suggest that haploinsufficiency for Egr1 plays a role in murine leukemogenesis, and in the development of AML/MDS characterized by abnormalities of chromosome 5.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Del(5q): gene dosage matters
- Matthew J. Walter
Blood 2007 110: 473-474.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
R. A. Larson
Therapy-related myeloid neoplasms
Haematologica,
April 1, 2009;
94(4):
454 - 459.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zhang, J. Wong, M. Klinger, M. T. Tran, K. M. Shannon, and N. Killeen
Mll5 contributes to hematopoietic stem cell fitness and homeostasis
Blood,
February 12, 2009;
113(7):
1455 - 1463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Peng, S. M. Kitchen, R. A. West, R. Sigler, K. M. Eisenmann, and A. S. Alberts
Myeloproliferative Defects following Targeting of the Drf1 Gene Encoding the Mammalian Diaphanous Related Formin mDia1
Cancer Res.,
August 15, 2007;
67(16):
7565 - 7571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pedersen-Bjergaard, M. T. Andersen, and M. K. Andersen
Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
Hematology,
January 1, 2007;
2007(1):
392 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Larson
Etiology and Management of Therapy-Related Myeloid Leukemia
Hematology,
January 1, 2007;
2007(1):
453 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
